How should we best sequence the new targeted therapies in relapsed B-ALL?

During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How should we best sequence the new targeted therapies in relapsed B-ALL?

To begin with, Curran discusses the approval of several novel agents such as CAR T-cell therapy, Inotuzumab , and blinatumomab, which have changed the treatment landscape in this field. She expands on what to consider when choosing the appropriate therapy for patients in the relapse setting, including efficacy, disease burden, toxicity, and whether the patient is a stem cell transplant candidate. Curran believes these are exciting times, with the field moving quickly forward which will lead to a better utilisation of novel agents in the future.